A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...
Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...
Niraparib approved for all-comers whose tumors responded to chemotherapy Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency. The FDA restricted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback